Nathan Connell: A Groundbreaking Study Has Just Been Published in Blood, From Vincent Muczynski and Colleagues
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:
”Exciting news in the field of hemophilia A gene therapy!
A groundbreaking study, “Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody,” has just been published in Blood, from Vincent Muczynski and colleagues (including Olivier Christophe, Caterina Casari, Gavin Ling, Peter Lenting, and Amit Nathwani).
This research addresses significant hurdles in current adeno-associated virus (AAV)-based treatments, specifically the challenge of packaging the large factor VIII (FVIII) transgene and concerns over long-term durability.
Key Scientific Takeaways:
- Novel Approach: Researchers developed AAV8-Bi8, a liver-directed gene therapy encoding a highly compact, 54.5 kDa single-chain FVIII-mimetic antibody, Bi8. This smaller cassette (4.4 kb) is much easier to package into the AAV vector.
- Efficacy: In FVIII-deficient mice, a single administration of AAV8-Bi8 resulted in dose-dependent, durable expression and complete phenotypic correction of bleeding.
- Clinical Equivalence: The therapeutic effect was comparable to emicizumab, the current market standard, but delivered via a gene therapy platform.
- Future Potential: This strategy offers a more flexible and efficient platform for long-term haemostatic control, including for patients who have developed inhibitors to FVIII.
A highly promising development that could significantly advance treatment options for hemophilia patients. Read the full article to dive into the data!”
Read the full article in Blood.
Article: Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody
Authors: Vincent Muczynski Corresponding Author , Olivier D. Christophe, Lewis Tanner, Charlotte Vayssiere, Alice Guérin, Caterina Casari, Jenny Hazel McIntosh, Doyoung Lee, Gavin Ling, Satyen Harish Gohil, Peter J Lenting, Edward G Tuddenham, Amit C Nathwani

Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities
-
Feb 22, 2026, 09:12Arun V J։ The Hidden Risks in Every Blood Bag
-
Feb 22, 2026, 08:56Parandzem Khachatryan։ How Hard Is It to Be a Mom, a Wife, a Professor, and a Doctor All at Once?
-
Feb 22, 2026, 08:46Anirban Sen Gupta Presents Bioinspired Platelet Surrogates at MTEC
-
Feb 22, 2026, 08:31Heghine Khachatryan: Advancing Care for Women and Girls with Bleeding Disorders is A Matter of Equity